The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes

Journal of Infectious Diseases

Volumn 201, Issue 1, 2010, Pages 123-131

  Serra Casas, Elisa ^a,b   Menéndez, Clara ^a,b   Bardají, Azucena ^a,b   Quintó, Llorenç ^a   Dobaño, Carlota ^a,b   Sigauque, Betuel ^a,b,c   Jiménez, Alfons ^a   Mandomando, Inacio ^a,b,c   Chauhan, Virander S ^d   Chitnis, Chetan E ^d   Alonso, Pedro L ^a,b   Mayor, Alfredo ^a,b,e  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b Manhiça Health Research Center   (Mozambique)

^c INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CHONDROITIN 4 SULFATE; FANSIDAR; MEMBRANE ANTIGEN; PARASITE ANTIBODY; PLACEBO;

ADULT; ANEMIA; ANTIBODY RESPONSE; ARTICLE; CELL LYSATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MORBIDITY; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, PROTOZOAN; ANTIMALARIALS; CHEMOPREVENTION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FETAL BLOOD; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INSECTICIDE-TREATED BEDNETS; MALARIA, FALCIPARUM; MOZAMBIQUE; PLACEBOS; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PYRIMETHAMINE; SULFADOXINE; YOUNG ADULT;

EID: 71949084923     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/648595     Document Type: Article

References (40)

1. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ 1983; 61:1005-1016
2. 2. Menendez C, Ordi J, Ismail MR, et al. The impact of placental malaria on gestational age and birth weight. J Infect Dis 2000; 181:1740-1745 (Pubitemid 30387768)
3. World Health Organization. A strategic framework for malaria prevention and control during pregnancy in the African region. Geneva: World Health Organization: AFR/MAL, 2004.
4. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine- pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998; 59:813-822
5. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine- pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999; 353:632-636
6. 6. Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, Molyneux ME. Intermittent sulfadoxine-pyrimethamine in pregnancy effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-1999. Trans R Soc Trop Med Hyg 2000; 94:549-553 (Pubitemid 30793839)
7. 7. Staalsoe T, Shulman CE, Dorman EK, Kawuondo K, Marsh K, Hviid L. Intermittent preventive sulfadoxine-pyrimethamine treatment of Primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria. Infect Immun 2004; 72:5027-5030 (Pubitemid 39223386)
8. Mount AM, Mwapasa V, Elliott SR, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004; 363:1860-1867
9. 9. Dembo EG, Mwapasa V, Montgomery J, et al. Impact of human immunodeficiency virus infection in pregnant women on variant-specific immunity to malaria. Clin Vaccine Immunol 2008; 15:617-621 (Pubitemid 351967052)
10. Voller A, Wilson H. Immunological aspects of a population under prophylaxis against malaria. Br Med J 1964; 2:551-552
11. 11. Cornille-Brogger R, Mathews HM, Storey J, Ashkar TS, Brogger S, Molineaux L. Changing patterns in the humoral immune response to malaria before, during, and after the application of control measures: a longitudinal study in the West African savanna. Bull World Health Organ 1978; 56:579-600. (Pubitemid 9017092)
12. Bradley-Moore AM, Greenwood BM, Bradley AK, et al. Malaria chemoprophylaxis with chloroquine in young Nigerian children. I. Its effect on mortality, morbidity and the prevalence of malaria. Ann Trop Med Parasitol 1985; 79:549-562
13. 13. Otoo LN, Snow RW, Menon A, Byass P, Greenwood BM. Immunity to malaria in young Gambian children after a two-year period of chemoprophylaxis. Trans R Soc Trop Med Hyg 1988; 82:59-65. (Pubitemid 18056239)
14. Lege-Oguntoye L, Onyemelukwe GC, Maiha BB, Udezue EO, Eckerbom S. The effect of short-term malaria chemoprophylaxis on the immune response of semi-immune adult volunteers. East Afr Med J 1990; 67: 770-778
15. Hogh B, Thompson R, Lobo V, et al. The influence of Maloprim chemoprophylaxis on cellular and humoral immune responses to Plasmodium falciparum asexual blood stage antigens in schoolchildren living in a malaria endemic area of Mozambique. Acta Trop 1994; 57:265-277
16. Quelhas D, Puyol L, Quinto L, et al. Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clin Vaccine Immunol 2008; 1282-1291
17. Collins WE, Spencer HC, Kaseje DC, et al. Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. III. Serologic studies. Ann Trop Med Parasitol 1987; 81:90-97
18. Mutabingwa TK, Malle LN, Eling WM, Verhave JP, Meuwissen JH, de Geus A. Malaria chemosuppression in pregnancy. III. Its effects on the maternal malaria immunity. Trop Geogr Med 1993; 45:103-109
19. Staalsoe T, Megnekou R, Fievet N, et al. Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia. J Infect Dis 2001; 184:618-626
20. Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 1996; 272:1502-1504
21. Ricke CH, Staalsoe T, Koram K, et al. Plasma antibodies from malariaexposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. J Immunol 2000; 165:3309-3316
22. O'Neil-Dunne I, Achur RN, Agbor-Enoh ST, et al. Gravidity-dependent production of antibodies that inhibit binding of Plasmodium falciparum-infected erythrocytes to placental chondroitin sulfate proteoglycan during pregnancy. Infect Immun 2001; 69:7487-7492
23. Duffy PE, Fried M. Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infect Immun 2003; 71:6620-6623
24. Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, Hviid L. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 2004; 363:283-289
25. Rasheed FN, Bulmer JN, De Francisco A, et al. Relationships between maternal malaria and malarial immune responses in mothers and neonates. Parasite Immunol 1995; 17:1-10.
26. Xi G, Leke RG, Thuita LW, et al. Congenital exposure to Plasmodium falciparum antigens: prevalence and antigenic specificity of in uteroproduced antimalarial immunoglobulin M antibodies. Infect Immun 2003; 71:1242-1246
27. Broen K, Brustoski K, Engelmann I, Luty AJ. Placental Plasmodium falciparum infection: causes and consequences of in utero sensitization to parasite antigens. Mol Biochem Parasitol 2007; 151:1-8.
28. Mutabingwa TK, Malle LN, Verhave JP, Eling WM, Meuwissen JH, de Geus A. Malaria chemosuppression during pregnancy. IV Its effects on the newborn's passive malaria immunity. Trop Geogr Med 1993; 45:150-156
29. INDEPTH-Network. Population and health in developing countries. Ottawa, Canada: International Development Research Centre, 2006.
30. 30. Menendez C, Bardaji A, Sigauque B, et al. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS ONE 2008; 3:e1934. (Pubitemid 351984114)
31. Alonso PL, Smith T, Schellenberg JR, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994; 344:1175-1181
32. 32. Ismail MR, Ordi J, Menendez C, et al. Placental pathology in malaria: a histological, immunohistochemical, and quantitative study. Hum Pathol 2000; 31:85-93. (Pubitemid 30054392)
33. Mayor A, Serra-Casas E, Bardaji A, et al. Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. Malar J 2009; 8:9.
34. Kinyanjui SM, Howard T, Williams TN, Bull PC, Newbold CI, Marsh K. The use of cryopreserved mature trophozoites in assessing antibody recognition of variant surface antigens of Plasmodium falciparum-infected erythrocytes. J Immunol Methods 2004; 288:9-18.
35. 35. Reitmeir P, Wassmer G. Resampling-based methods for the analysis of multiple endpoints in clinical trials. Stat Med 1999; 18:3453-3462 (Pubitemid 30041359)
36. Kariuki SK, ter Kuile FO, Wannemuehler K, et al. Effects of permethrintreated bed nets on immunity to malaria in western Kenya. I. Antibody responses in pregnant women and cord blood in an area of intense malaria transmission. Am J Trop Med Hyg 2003; 68:61-67
37. Riley EM, Wagner GE, Ofori MF, et al. Lack of association between maternal antibody and protection of African infants from malaria infection. Infect Immun 2000; 68:5856-5863
38. Ned RM, Price AE, Crawford SB, et al. Effect of placental malaria and HIV infection on the antibody responses to Plasmodium falciparum in infants. J Infect Dis 2008; 198:1609-1619
39. Le Hesran JY, Cot M, Personne P, et al. Maternal placental infection with Plasmodium falciparum and malaria morbidity during the first 2 years of life. Am J Epidemiol 1997; 146:826-831
40. Schwarz NG, Adegnika AA, Breitling LP, et al. Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis 2008; 47: 1017-1025